1. Japan Stocks

  2. •

    Technology

  3. •

    Hardware, Equipment & Parts
JEOL Ltd.

JEOL Ltd.

JELLF
JEOL Ltd.US flagOther OTC
37.00
USD
- -
- -
1.80BMarket Cap
JEOL Ltd.
JELLF
(Other OTC)

Recent

price

37.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,165.35
1,922.88
2,125.17
2,034.23
2,493.97
1,974.01
2,222.28
2,063.48
2,164.38
2,303.5
2,426.74
2,285.72
2,781.73
3,187.36
3,413.07
3,847.49
2,067.36
Revenue per Share
7.02
1.33
-231.19
40.82
100.03
41.21
84.63
12.31
93.8
122.95
110.92
77.51
246.76
349.32
424.91
365.55
277.71
Basic EPS, GAAP
-22.68
47.49
35.25
-182.22
11.62
152.24
110.19
-66.05
99.6
67.68
17.3
-75.98
423.83
-59.52
231.52
368.54
- -
Free Cash Flow per Basic Share
8
7.05
8
0.08
12.83
11.03
9.96
13.99
13.99
18.07
24.2
24.19
26.19
66.34
69.34
113.39
- -
Dividend per Share
517.83
512.2
273.01
313.84
478.4
424.03
498.67
497.02
576.83
681.72
768.45
821.68
1,247.55
1,498.98
1,853.56
2,103.89
1,997.46
Book Value per Share
629.92
570.8
322.64
466.94
601.96
544.23
590.03
605.46
719.44
814.34
824.52
980.55
1,658.07
1,941.54
2,412.79
2,599.13
2,521
Tangible Book Value per Share
39
39
39
39
40
48
48
48
48
48
48
48
50
51
51
51
51
Basic Weighted Avg Shares
84,769
75,274
83,191
79,629
99,331
95,379
107,373
99,698
104,570
111,289
117,243
110,439
138,408
162,689
174,336
196,695
105,618
Sales/Revenue/Turnover
0.6
1.36
-1.41
3.73
6.07
3.07
5.72
2.08
3.76
5.99
6
4.73
10.22
14.85
15.79
18.05
18.22
Operating Margin (%)
3,403
3,167
2,890
2,276
2,619
3,086
3,245
2,894
3,037
3,124
3,560
4,216
4,334
4,922
4,747
5,178
- -
Depreciation Expense
275
52
-9,050
1,598
3,984
1,991
4,089
595
4,532
5,940
5,359
3,745
12,278
17,830
21,704
18,688
14,188
Net Income, GAAP
54.22
165.08
- -
17.62
10.47
43.02
29.12
73.79
5.5
20.95
28.06
33.29
26.26
24.81
26.35
25.13
26.21
Effective Tax Rate (%)
0.32
0.07
-10.88
2.01
4.01
2.09
3.81
0.6
4.33
5.34
4.57
3.39
8.87
10.96
12.45
9.5
13.43
Profit Margin (%)
18,030
16,227
7,088
11,586
25,664
26,114
26,780
33,011
30,775
33,167
35,585
41,402
67,692
78,154
81,754
96,497
85,706
Working Capital
16,203
14,182
8,678
9,002
15,469
16,110
12,221
18,610
13,537
10,603
12,914
17,618
11,754
7,106
8,348
4,297
5,102
LT Debt
25,752
24,046
14,388
19,830
28,792
30,451
32,087
32,285
37,387
41,591
45,078
50,998
85,903
101,892
125,513
136,651
131,640
Total Equity
0.34
-1.02
- -
4.33
8.58
2.48
6.66
0.86
5.87
8.3
7.22
4.32
10.8
16.03
15.22
17.74
10.54
Return on Invested Capital (%)
1.13
-0.17
- -
4.35
8.39
4.03
7.94
1.26
8.88
11.42
9.13
5.55
16.26
21.27
21.83
16.52
13.95
Return on Capital (%)
1.36
0.26
-58.88
13.91
25.43
10.07
18.34
2.47
17.47
19.54
15.3
9.75
24.13
25.73
25.36
18.48
15.4
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
7,433
- -
5,686
LT Borrowings
7,584
- -
5,102
LT Finance Leases
764
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
- -
51
Market Capitalization
17,865
18,998
345,950

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
169,854
- -
169,408
Cash, Cash Equivalents & STI
31,504
- -
39,646
Accounts Receivable, Net
56,034
- -
43,741
Inventories
76,810
- -
82,228
Total Current Liabilities
88,100
- -
83,702
Payables & Accruals
- -
- -
- -
ST Debt
7,433
- -
5,686
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.36%
26.45%
8.87%
Free Cash Flow
-230.28%
-351.58%
59.32%
Net Income, GAAP
95.37%
50.16%
-13.9%
Sales/Revenue/Turnover
7.92%
11.41%
12.83%
Total Cash Common Dividend
- -
- -
63.66%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28,671
40,047
38,159
67,459
174,336
2025
- -
- -
- -
- -
196,695
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33.76
- -
- -
- -
424.91
2025
- -
- -
- -
- -
365.55
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
69.34
2025
- -
- -
- -
- -
113.39
2026
- -
- -
- -
- -
- -
Similar Companies
ITEQ Corporation (6213.TW)
NOTE AB (publ) (NOTE.ST)
Fitbit, Inc. (5FB.DE)
IKIO Technologies Ltd (IKIO.NS)
Beijing Century Real Technology Co.,Ltd (300150.SZ)
Western Digital Corporation Common Stock Ex-distribution When-Issued (WDCVV)
Business
JEOL Ltd. (TSE: 6951) develops and manufactures scientific and metrology instruments, semiconductor and industrial equipment, and medical equipment. The company operates four main business segments: electron optics, which produces transmission electron microscopes, scanning electron microscopes, focused ion beam systems, electron probe micro analyzers, photoelectron spectrometers, auger micro probes, soft X-ray emission spectrometers, energy-dispersive X-ray fluorescence spectrometers, electron diffractometers and related peripherals; analytical instruments, including nuclear magnetic resonance spectrometers, electron spin resonance spectrometers and mass spectrometers such as MALDI time-of-flight, gas chromatograph-mass and liquid chromatograph-mass types; semiconductor equipment featuring electron beam lithography systems using variable shaped and spot beam technologies; industrial equipment comprising high power electron beam sources, deposition sources, plasma sources, powder feeders and electron beam metal 3D printers; and medical equipment centered on the BioMajesty series of clinical chemistry analyzers. JEOL maintains global operations with subsidiaries across North America, Europe and Asia, serving academic, industrial and research customers in fields such as nanotechnology, biotechnology, semiconductors, drug discovery and batteries. Founded in 1949 and headquartered at 3-1-2 Musashino, Akishima, Tokyo, the company employs around 3,600 people consolidated and reported sales of JPY197 billion for the fiscal year ended March 2025. Recent developments include the acquisition of Japan Superconductor Technology, Inc. (JASTEC) from Kobe Steel, finalized in early January 2025 to bolster superconducting wire and magnet capabilities; construction of new facilities at its Akishima main office and Yamagata plant announced in May 2025 under the Evolving Growth 2.0 medium-term plan to enhance productivity and smart factory operations; a March 2025 partnership with WEGO Shingene Medical Technology Co., Ltd. of China; and the September 2025 divestiture of its clinical chemistry medical equipment business to Sysmex Corporation, accompanied by the establishment of a dedicated medical equipment subsidiary.